Floatz logo

ALMURTIDE

Malignant Tumor of Colon

Robert WesolowskiSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malignant Tumor of Colon cohort.

Asset / SponsorPhaseRating
Her-2 Vaccine
Robert Wesolowski
Phase 1CC
Egfrbi-Armed Autologous Activated T Cells
Barbara Ann Karmanos Cancer Institute
Phase 1C

Same molecule, other indications

ALMURTIDE is also rated in:

Malignant Solid TumourDormant
CC
Indicative ·
47 / 100
View asset →
GISTDormant
CC
Indicative ·
46 / 100
View asset →
Breast CancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →